Compare · ARGX vs CGTX
ARGX vs CGTX
Side-by-side comparison of argenx SE (ARGX) and Cognition Therapeutics Inc. (CGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CGTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.38B, about 595.7x CGTX ($91.3M).
- Over the past year, ARGX is up 56.2% and CGTX is up 67.1% - CGTX leads by 10.9 points.
- CGTX has been more active in the news (8 items in the past 4 weeks vs 2 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 4 for CGTX).
- Company
- argenx SE
- Cognition Therapeutics Inc.
- Price
- $876.49-0.18%
- $1.02-7.27%
- Market cap
- $54.38B
- $91.3M
- 1M return
- +1.71%
- -11.69%
- 1Y return
- +56.17%
- +67.08%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 2
- 8
- Recent ratings
- 25
- 4
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Cognition Therapeutics Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest CGTX
- Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
- Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Director Khattar Jack A. was granted 25,000 shares, increasing direct ownership by 52% to 73,500 units (SEC Form 4)
- Director Monia Brett P was granted 25,000 shares, increasing direct ownership by 52% to 73,500 units (SEC Form 4)
- Director Wallace Peggy was granted 25,000 shares, increasing direct ownership by 29% to 111,461 units (SEC Form 4)
- Director Richstone Ellen B was granted 25,000 shares, increasing direct ownership by 43% to 83,500 units (SEC Form 4)
- Director Fletcher Aaron G.L. was granted 25,000 shares (SEC Form 4)
- Cognition Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045